ABSTRACT
Importance Epigenetic accelerated aging is associated with exposure to social and economic adversity and may increase risk of premature morbidity and mortality. However, no studies have included measures of structural racism and few have compared estimates within or across the 1st and 2nd generation of epigenetic clocks (the latter additionally trained on phenotypic data).
Objective To determine if accelerated epigenetic aging is associated with exposures to diverse measures of racialized, economic, and environmental injustice measured at different levels and time periods.
Design Cross-sectional My Body My Story Study (MBMS; US, 2008-2010) and Exam 5 Multi-Ethnic Atherosclerosis Study (MESA; US, 2010-2012). MBMS DNA extraction: 2021; linkage of structural measures to MBMS and MESA: 2022.
Setting MBMS recruited a random sample of US-born Black non-Hispanic (BNH) and white non-Hispanic (WNH) participants from 4 community health centers in Boston, MA. The MESA Exam 5 epigenetic component included 975 randomly selected US-born BNH, WNH, and Hispanic participants from four field sites: Baltimore, MD; Forsyth County, NC; New York City, NY; St. Paul, MN.
Participants US-born persons (MBMS: 224 BNH, 69 WNH; MESA: 229 BNH, 555 WNH, 191 Hispanic).
Main outcome and measures 10 epigenetic clocks (six 1st generation; four 2nd generation), computed using DNA methylation data (DNAm) from blood spots (MBMS; N = 293) and purified monocytes (MESA; N = 975).
Results Among Black non-Hispanic MBMS participants, epigenetic age acceleration was associated with being born in a Jim Crow state by 0.14 standard deviations (95% confidence interval [CI] 0.00, 0.27) and with birth state conservatism (0.06, 95% CI 0.00, 0.05), pooling across all clocks, as was low parental education for both Black non-Hispanic and white non-Hispanic MBMS participants (respectively: 0.24, 95% CI 0.08, 0.39, and 0.27, 95% CI 0.03, 0.51. Adult impoverishment was positively associated with the pooled 2nd generation clocks among the MESA participants (Black non-Hispanic: 0.06, 95% CI 0.01, 0.12; white non-Hispanic: 0.05, 95% CI 0.01, 0.08; Hispanic: 0.07, 95% CI 0.01, 0.14).
Conclusions and Relevance Epigenetic accelerated aging may be one of the biological mechanisms linking exposure to racialized and economic injustice to well-documented inequities in premature morbidity and mortality.
KEY POINTS Question: Is accelerated epigenetic aging associated with exposure to racialized, economic, and environmental injustice?
Findings: In the US cross-sectional My Body My Story (MBMS; n = 263) and Multi-Ethnic Atherosclerosis Study (MESA, Exam 5; n = 1264)), epigenetic accelerated aging was associated with Jim Crow birth state for MBMS Black non-Hispanic participants (by 0.14 standard deviations, 95% confidence interval 0.00, 0.27) and similarly with low parental education (MBMS: Black and white non-Hispanic participants) and adult impoverishment (MESA: Black and white non-Hispanic and Hispanic participants).
Meaning: Epigenetic accelerated aging may be a biological pathway for embodying racialized and economic injustice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work for this study was supported by the National Institutes of Health, National Institute of Minority and Health Disparities [grant number grant R01MD014304 to N.K. and C.R., as MPIs]. Additionally, GDS, CR, KT, MS, SHW work within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00011/1,3, & 5 and MC_UU-00032/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Prior funding supporting our work: a) The prior MBMS study was funded by the National Institutes of Health/National Institute on Aging (R01AG027122) and generation of the black carbon data for this study was supported by a pilot grant from the Harvard NIEHS Center (P30 ES000002). b) No additional grant funding to MESA was obtained for the conduct of this study whose Data Use Agreement (G638) was approved by MESA (on 11/22/2019) to use pre-existing MESA data. Support for generating these pre-existing MESA data is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. The MESA Epigenomics & Transcriptomics Studies were funded by NIH grants 1R01HL101250, 1RF1AG054474, R01HL126477, R01DK101921, and R01HL135009. This publication was developed under the Science to Achieve Results (STAR) research assistance agreements, No. RD831697 (MESA Air) and RD-83830001 (MESA Air Next Stage), awarded by the U.S Environmental Protection Agency (EPA). It has not been formally reviewed by the EPA. The views expressed in this document are solely those of the authors and the EPA does not endorse any products or commercial services mentioned in this publication. Funding for MESA SHARe genotyping was provided by NHLBI Contract N02-HL-6-4278. Genotyping was performed at the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) and at Affymetrix (Santa Clara, California, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB the Harvard T.H. Chan School of Public Health (Harvard University, Boston, MA, USA) gave ethical approval for this work (Protocol # IRB19-0524; June 10, 2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This study relied on three sources of data, each of which is subject to distinct data sharing stipulations: (1) the non-public data from the My Body, My Story (MBMS) study; (2) the non-public data from the Multi-Ethnic Study of Atherosclerosis (MESA; data use agreement G638); and (3) the public de-identified data from the US Census, the American Community Survey, and the State Policy Liberalism Index. Descriptions of these data sharing stipulations and how to access these data is provided at: https://www.hsph.harvard.edu/nancy-krieger/data-sharing-resources/
https://reporter.nih.gov/search/T1qnoiJCukWRK0Mcvk-CJA/project-details/10363700
https://www.hsph.harvard.edu/nancy-krieger/data-sharing-resources/
https://github.com/DNAmAndAdversity/CensusData
https://github.com/DNAmAndAdversity/DNAmAndAdversity_public
https://zenodo.org/records/10256923
https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/ZXZMJB
http://dx.doi.org/10.7910/DVN/ZXZMJB
